COLTHERES

Modelling and predicting sensitivity to targeted therapies in colorectal cancers

 Coordinatore UNIVERSITA DEGLI STUDI DI TORINO 

 Organization address address: Via Giuseppe Verdi 8
city: TORINO
postcode: 10124

contact info
Titolo: Prof.
Nome: Alberto
Cognome: Bardelli
Email: send email
Telefono: +39 0119933235
Fax: +39 0119933225

 Nazionalità Coordinatore Italy [IT]
 Sito del progetto http://www.coltheres.eu/
 Totale costo 8˙200˙254 €
 EC contributo 5˙999˙300 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2010-two-stage
 Funding Scheme CP-FP
 Anno di inizio 2011
 Periodo (anno-mese-giorno) 2011-01-01   -   2014-12-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI TORINO

 Organization address address: Via Giuseppe Verdi 8
city: TORINO
postcode: 10124

contact info
Titolo: Prof.
Nome: Alberto
Cognome: Bardelli
Email: send email
Telefono: +39 0119933235
Fax: +39 0119933225

IT (TORINO) coordinator 1˙507˙200.00
2    Horizon Discovery Limited

 Organization address address: CAMBRIDGE RESEARCH PARK
city: Cambridge
postcode: CB25 9TL

contact info
Titolo: Dr.
Nome: Christopher
Cognome: Torrance
Email: send email
Telefono: 441224000000
Fax: 441224000000

UK (Cambridge) participant 920˙520.00
3    STICHTING HET NEDERLANDS KANKER INSTITUUT

 Organization address address: PLESMANLAAN 121
city: AMSTERDAM
postcode: 1066 CX

contact info
Titolo: Prof.
Nome: Rene
Cognome: Bernards
Email: send email
Telefono: 31205121952
Fax: 31205121954

NL (AMSTERDAM) participant 641˙200.00
4    KATHOLIEKE UNIVERSITEIT LEUVEN

 Organization address address: Oude Markt 13
city: LEUVEN
postcode: 3000

contact info
Titolo: Ms.
Nome: Sofie
Cognome: Heroes
Email: send email
Telefono: 3216329979
Fax: 3216326515

BE (LEUVEN) participant 498˙400.00
5    Agendia BV

 Organization address address: Science Park 406
city: Amsterdam
postcode: 1098XH

contact info
Titolo: Dr.
Nome: Iris
Cognome: Simon
Email: send email
Telefono: +31 20 462 1542
Fax: +31 20 462 1505

NL (Amsterdam) participant 490˙500.00
6    FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE

 Organization address address: AVENIDA GRAN VIA HOSPITALET 199-203
city: L'HOSPITALET DE LLOBREGAT
postcode: 8908

contact info
Titolo: Ms.
Nome: Carole
Cognome: Amroune
Email: send email
Telefono: +34 93 260 7245
Fax: +34 93 260 7219

ES (L'HOSPITALET DE LLOBREGAT) participant 419˙200.00
7    THE UNIVERSITY OF LIVERPOOL

 Organization address address: Brownlow Hill, Foundation Building 765
city: LIVERPOOL
postcode: L69 7ZX

contact info
Titolo: Ms.
Nome: Jenny
Cognome: Lawson
Email: send email
Telefono: 441518000000
Fax: 441518000000

UK (LIVERPOOL) participant 348˙700.00
8    FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON

 Organization address city: Barcelona
postcode: 8035

contact info
Titolo: Dr.
Nome: Alejandro
Cognome: Piris Giménez
Email: send email
Telefono: 34934893021
Fax: 34934893884

ES (Barcelona) participant 333˙900.00
9    SWISS INSTITUTE OF BIOINFORMATICS

 Organization address address: Rue Michel Servet 1
city: GENEVE
postcode: 1211

contact info
Titolo: Ms.
Nome: Jocelyne
Cognome: Bocquet
Email: send email
Telefono: +41 21 692 4058
Fax: +41 21 692 4055

CH (GENEVE) participant 320˙880.00
10    AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA

 Organization address address: PIAZZA OSPEDALE MAGGIORE 3
city: MILANO
postcode: 20162

contact info
Titolo: Dr.
Nome: Salvatore
Cognome: Siena
Email: send email
Telefono: +39 02 6444 2291
Fax: +39 02 6444 2957

IT (MILANO) participant 314˙800.00
11    ARTTIC IN BRUSSELS SPRL

 Organization address address: RUE DE LIVOURNE 7 bte 4
city: BRUXELLES
postcode: 1060

contact info
Titolo: Mr.
Nome: Paul
Cognome: Crompton
Email: send email
Telefono: 3226723339
Fax: 3226721646

BE (BRUXELLES) participant 204˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

omics    cancer    predictive    sensitivity    trials    profiling    assays    models    biomarkers    patient    building    technologies    coltheres    right    data    screening    innovative    co    resistance    genomic    biomarker    prospectively    therapies    clinical    drug    genes   

 Obiettivo del progetto (Objective)

'Effective and long term treatment of cancer is now in sight, but will ultimately require an increasingly ‘personalised’ approach where the ‘right’ combination of drugs will be administered to the ‘right’ patients, based on a detailed understanding of their genetic background and their co-associated sensitivity or resistance ‘biomarkers’. Efforts are specifically required to identify validated risk and patient-response stratification criteria, which can then be used to rationally develop companion diagnostic assays and more stream-lined clinical trials. COLTHERES will address these key issues by: 1) Molecularly profiling colon cancer patient samples using multiple ‘omics based technologies for co-segregating lesions that could impart resistance to existing and emerging targeted therapies 2) The building and screening of predictive in vitro models based on this data, to enable the rapid and empirical determination of drug resistance biomarkers 3) The use of these models and of the clinical studies to prospectively screen for genes mediating resistance and sensitivity to targeted therapies in CRCs 4) The building of new algorithms to significantly accelerate the design of rational therapies, by integrating more predictive models, assays and biomarkers into all phases of drug discovery; including novel phase-0 (xenopatients) studies 5) The design of innovative and focused biomarker driven phase II trials based on knowledge gathered within the project

COLTHERES has assembled a unique consortium, from both academia and industrial SMEs, of world- experts in the areas of; • clinical design of innovative biomarker trials and improved therapeutic strategies • ‘omics technologies including genomic, transcriptomic, epigenomic and proteomic profiling • Functional genomic and disease model-generation • Bio-informatics and data analysis, to handle and interrogate the complexity of the data generated through the various approaches'

Introduzione (Teaser)

A main limitation of targeted therapies in colorectal cancer is the emergence of secondary resistance. European scientists are prospectively screening for genes that mediate such acquired resistance, aiming to identify specific drug resistance biomarkers.

Altri progetti dello stesso programma (FP7-HEALTH)

EUROSTAM (2012)

A Europe-wide Strategy to enhance Transplantation of highly sensitized patients on basis of Acceptable HLA Mismatches

Read More  

PRESTIGE (2010)

PREvention of Late Stent Thrombosis by an Interdisciplinary Global European effort

Read More  

BIO-COMET (2011)

"Bioreactor-based, clinically oriented manufacturing of engineered tissues"

Read More